ALK-Abelló Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Peter Halling

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Apr 27

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 06

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 17

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

Jan 30

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Dec 05

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Nov 11

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Sep 01

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 05

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

May 12

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Apr 21

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

Mar 31

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Dec 28

Calculating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Dec 07

ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet

Sep 11

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 21

CEO

Peter Halling (46 yo)

1.3yrs

Permanencia

Mr. Peter Halling is President & CEO of ALK-Abelló A/S from 2023. Mr. Peter Halling serves as Chief Executive Officer at Fertin Pharma A/S since August 2020. He has an extensive experience from working in...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Claus Solje	Executive VP	less than a year	kr.14.86m	sin datos
Søren Niegel	Executive VP of Commercial Operations & Member of Management Board	12yrs	kr.6.51m	0.020% DKK 6.6m
Henriette Mersebach	Executive VP Research & Development & Member of Management Board	1.2yrs	kr.7.18m	sin datos
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	no data	kr.350.00k	sin datos
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	no data	kr.270.00k	sin datos
Peter Halling	President & CEO	1.3yrs	sin datos	sin datos
Per Plotnikof	VP of Corporate Communications	no data	sin datos	sin datos
Hendrik Kees Nolte	Senior Vice President of Research & Development - North America and International Markets	7.2yrs	sin datos	sin datos
Christian Houghton	Head of Product Supply	5.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ALK B se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Katja Thalund	Project Director of Global CMC Development & Employee-elected Director	13.3yrs	kr.350.00k	sin datos
Lise Maerkedahl	Project Director of Global Research & Employee-elected Director	1.2yrs	kr.270.00k	sin datos
Jesper Hoiland	Independent Director	1.2yrs	kr.366.00k	sin datos
Lene Skole-Sorensen	Vice Chairman of the Board	10.3yrs	kr.900.00k	sin datos
Anders Hedegaard	Independent Chairman of the Board	4.2yrs	kr.1.33m	sin datos
Lars Holmqvist	Director	9.2yrs	kr.446.00k	sin datos
Gitte Aabo	Independent Director	3.2yrs	kr.523.00k	sin datos
Alan Main	Independent Director	2.2yrs	kr.450.00k	sin datos
Bertil Lindmark	Independent Director	3.2yrs	kr.500.00k	sin datos
Nanna Carlson	Employee Representative Director	5.2yrs	kr.350.00k	sin datos
Johan Smedsrud	Employee Representative Director	5.2yrs	kr.350.00k	sin datos

4.2yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de ALK B se considera experimentada (4.1 años de antigüedad promedio).

ALK-Abelló Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insider recently sold kr.9.0m worth of stock

Alk-Abelló A/S Announces Executive Changes

ALK Announces Management Changes

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Recent updates

Investor sentiment improves as stock rises 17%

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Insider recently sold kr.9.0m worth of stock

Price target increased by 7.8% to kr.121

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Price target decreased by 7.3% to kr.109

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Price target decreased by 9.2% to kr.116

Investor sentiment deteriorates as stock falls 15%

New major risk - Share price stability

Alk-Abelló A/S Announces Executive Changes

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Price target decreased by 8.5% to kr.129

Investor sentiment deteriorates as stock falls 22%

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

ALK Announces Management Changes

Full year 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Price target decreased to kr.161

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Now 20% undervalued after recent price drop

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 21% undervalued

Alk-Abelló A/S Announces Executive Changes

First quarter 2022 earnings: Revenues exceed analyst expectations

Now 20% undervalued

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

Less than half of directors are independent

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?